Centre Director at Healthpharm 2024

From April 9 to 10, the HealthPharm 2024 SEE Forum & Fair was held at the Chamber of Commerce and Industry of Serbia, while the third day of the Forum was at the Faculty of Law of the University of Belgrade. On the first day, the director of the Centre for the Fourth Industrial Revolution in Serbia, Jelena Bojović, took part as an opening speaker and also participated as a panelist.

In her introductory speech, Bojović highlighted the potential that artificial intelligence has in the health and pharmaceutical sectors in the region, as well as how the Centre in Serbia can use such potential. After that, Bojović participated in a panel entitled, ” Western Balkans E-Health and E-Pharma: How to use an AI For social good?”

The panel was moderated by Srđan Jovanović on behalf of HTEC Group and HUMEDS, and the discussion provided a dynamic platform for the exchange of ideas on the use of technology for the benefit of society, paving the way for a more efficient, accessible, and sustainable health ecosystem in the region. The panel also included Jelena Đerišilo from IBM, Milan Gospić from Microsoft Serbia, Bojan Kisić from NITES Group, Vukašin Radulović, in front of NALED, and Bogdan Gecić, founder and partner of Gecić Law.

This three-day event brought together interested parties in the field of medicine and pharmacy in the Western Balkans, with a focus on business and legal issues. The organizer of the event is Harmonius, an independent organization, an association of scientists and researchers in the field of legal studies.

One of the examples of the use of artificial intelligence is a project that was implemented in cooperation between C4IR Serbia, Heliant, and the Institute for Artificial Intelligence in Serbia. Models were created for the detection of rare diseases, with the potential for further development. At the center of this project is the Clinical Center of Serbia, and the development was based on the example of Fabry’s disease. The idea is to use artificial intelligence to identify patients who are more likely to get this disease.

Source: Heliant.

© Centre for the Fourth Industrial Revolution.